- Sihem BENSALEM* & Amina KHODJA
- Endocrinology-Diabetology and Metabolic diseases, Regional University Military Hospital Commander Abdellali BENBAATOUCHE (HMRUC) Constantine, Faculty of Medicine, University Constantine 3, ALGERIA
- DOI: 10.5281/zenodo.20391279
Primary hyperparathyroidism is a common endocrinopathy
characterized by the autonomous production of parathyroid hormone (PTH),
leading to hypercalcemia and hypophosphatemia. Although often diagnosed at an
asymptomatic stage, its clinical manifestations can include rare but classic
bone and renal complications, such as brown tumors. We report the case of a
73-year-old female patient who presented with an osteolytic swelling of the
maxilla. Initial imaging and biopsy suggested a benign giant cell tumor. However,
a complete phosphocalcemic panel revealed severe hypercalcemia (2.90 mmol/L),
hypophosphatemia (0.65 mmol/L), and a markedly elevated intact PTH (500 pg/mL),
confirming the diagnosis of primary hyperparathyroidism. Cervical computed
tomography localized a right parathyroid adenoma. The patient successfully
underwent targeted parathyroidectomy, which normalized biochemical parameters
and led to the regression of the bone lesion. This case illustrates an atypical
presentation where a maxillary brown tumor was the initial revealing sign, and
underscores the crucial importance of a multidisciplinary diagnostic approach.
Any giant cell tumor, particularly in the maxilla, should prompt a thorough
endocrinological workup, including measurement of calcium, phosphate, and PTH.
Ignoring this association could delay the diagnosis and expose the patient to
serious complications. Optimal management requires close collaboration between
endocrinologists, maxillofacial surgeons, radiologists, and pathologists to
treat both the local tumor and the underlying metabolic disorder.

